154 related articles for article (PubMed ID: 9473684)
21. Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents.
Sackett DL; Giannakakou P; Poruchynsky M; Fojo A
Cancer Chemother Pharmacol; 1997; 40(3):228-32. PubMed ID: 9219506
[TBL] [Abstract][Full Text] [Related]
22. Estramustine depolymerizes microtubules by binding to tubulin.
Dahllöf B; Billström A; Cabral F; Hartley-Asp B
Cancer Res; 1993 Oct; 53(19):4573-81. PubMed ID: 8402630
[TBL] [Abstract][Full Text] [Related]
23. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry.
Verdier-Pinard P; Wang F; Martello L; Burd B; Orr GA; Horwitz SB
Biochemistry; 2003 May; 42(18):5349-57. PubMed ID: 12731876
[TBL] [Abstract][Full Text] [Related]
24. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel.
Hari M; Yang H; Zeng C; Canizales M; Cabral F
Cell Motil Cytoskeleton; 2003 Sep; 56(1):45-56. PubMed ID: 12905530
[TBL] [Abstract][Full Text] [Related]
25. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
[TBL] [Abstract][Full Text] [Related]
26. Class III beta-tubulin and gamma-tubulin are co-expressed and form complexes in human glioblastoma cells.
Katsetos CD; Dráberová E; Smejkalová B; Reddy G; Bertrand L; de Chadarévian JP; Legido A; Nissanov J; Baas PW; Dráber P
Neurochem Res; 2007 Aug; 32(8):1387-98. PubMed ID: 17406983
[TBL] [Abstract][Full Text] [Related]
27. Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
Yang CH; Wang C; Ojima I; Horwitz SB
J Nat Prod; 2018 Mar; 81(3):600-606. PubMed ID: 29517223
[TBL] [Abstract][Full Text] [Related]
28. Estramustine: a novel radiation enhancer in human carcinoma cells.
Ryu S; Gabel M; Khil MS; Lee YJ; Kim SH; Kim JH
Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):99-104. PubMed ID: 7916009
[TBL] [Abstract][Full Text] [Related]
29. Rationalization of paclitaxel insensitivity of yeast β-tubulin and human βIII-tubulin isotype using principal component analysis.
Das L; Bhattacharya B; Basu G
BMC Res Notes; 2012 Aug; 5():395. PubMed ID: 22849332
[TBL] [Abstract][Full Text] [Related]
30. Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule.
Giannakakou P; Villalba L; Li H; Poruchynsky M; Fojo T
Int J Cancer; 1998 Jan; 75(1):57-63. PubMed ID: 9426691
[TBL] [Abstract][Full Text] [Related]
31. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine.
Speicher LA; Barone LR; Chapman AE; Hudes GR; Laing N; Smith CD; Tew KD
J Natl Cancer Inst; 1994 May; 86(9):688-94. PubMed ID: 7908988
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Pienta KJ; Smith DC
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
[TBL] [Abstract][Full Text] [Related]
33. [Antimitotic agents].
Fukuoka K; Saijo N
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1519-25. PubMed ID: 9309150
[TBL] [Abstract][Full Text] [Related]
34. Estramustine resistance correlates with tau over-expression in human prostatic carcinoma cells.
Sangrajrang S; Denoulet P; Millot G; Tatoud R; Podgorniak MP; Tew KD; Calvo F; Fellous A
Int J Cancer; 1998 Aug; 77(4):626-31. PubMed ID: 9679768
[TBL] [Abstract][Full Text] [Related]
35. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization.
Dumontet C; Jaffrezou JP; Tsuchiya E; Duran GE; Chen KG; Derry WB; Wilson L; Jordan MA; Sikic BI
Bull Cancer; 2004 May; 91(5):E81-112. PubMed ID: 15568225
[TBL] [Abstract][Full Text] [Related]
36. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism.
Poruchynsky MS; Giannakakou P; Ward Y; Bulinski JC; Telford WG; Robey RW; Fojo T
Biochem Pharmacol; 2001 Dec; 62(11):1469-80. PubMed ID: 11728383
[TBL] [Abstract][Full Text] [Related]
37. Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells.
Tamura D; Arao T; Nagai T; Kaneda H; Aomatsu K; Fujita Y; Matsumoto K; De Velasco MA; Kato H; Hayashi H; Yoshida S; Kimura H; Maniwa Y; Nishio W; Sakai Y; Ohbayashi C; Kotani Y; Nishimura Y; Nishio K
Cancer Med; 2013 Apr; 2(2):144-54. PubMed ID: 23634282
[TBL] [Abstract][Full Text] [Related]
38. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
[TBL] [Abstract][Full Text] [Related]
39. Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines.
Serafin AM; Bohm L
Urol Oncol; 2005; 23(2):123-9. PubMed ID: 15869997
[TBL] [Abstract][Full Text] [Related]
40. Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells.
Li Y; Hong X; Hussain M; Sarkar SH; Li R; Sarkar FH
Mol Cancer Ther; 2005 Mar; 4(3):389-98. PubMed ID: 15767548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
